1. GPCR/G Protein
    Neuronal Signaling
  2. 5-HT Receptor
  3. SB-200646

SB-200646 

Cat. No.: HY-103129A
Handling Instructions

SB-200646 is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646 is orally active and has electrophysiological and anxiolytic properties in vivo.

For research use only. We do not sell to patients.

SB-200646 Chemical Structure

SB-200646 Chemical Structure

CAS No. : 143797-63-1

Size Stock
100 mg   Get quote  
250 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Other In-stock Forms of SB-200646:

Other Forms of SB-200646:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

SB-200646 is the first selective 5-HT2B/2C over 5-HT2A receptor antagonist with pKi values of 7.5, 6.9 and 5.2 for 5-HT2B, 5-HT2C and 5-HT2A, respectively. SB-200646 is orally active and has electrophysiological and anxiolytic properties in vivo[1][2].

IC50 & Target[1][2]

5-HT2B Receptor

7.5 (pKi)

5-HT2C Receptor

6.9 (pKi)

5-HT2A Receptor

5.2 (pKi)

In Vitro

SB-200646A (4 μM) abolishes the ethanol-induced increase in miniature inhibitory postsynaptic current (mIPSC) frequency and had no effect on basal mIPSC frequency[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

SB-200646A (20 mg/kg; intravenous injection; daily; for 21 days; male albino Sprague-Dawley rats) treatment significantly decreases the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons[1].
The i.v. administration of 4-16 mg/kg of SB-200646A significantly increases the firing rate and % events as bursts in spontaneously active VTA dopaminergic neurons and significantly increases the % events as burst in substantia nigra pars compacta (SNC) dopaminergic neurons[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male albino Sprague-Dawley rats (200-225 g at the beginning of treatment and 300-350 g at the time of the experiment)[1]
Dosage: 20 mg/kg
Administration: Intravenous injection; daily; for 21 days
Result: Significantly decreased the number of spontaneously active ventral tegmental area (VTA) dopaminergic neurons.
Molecular Weight

266.30

Formula

C₁₅H₁₄N₄O

CAS No.

143797-63-1

SMILES

O=C(NC1=CC=CN=C1)NC2=CC3=C(N(C)C=C3)C=C2

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2

Keywords:

SB-200646SB200646SB 2006465-HT ReceptorSerotonin Receptor5-hydroxytryptamine Receptor5-HT2B5-HT2CSNCdopaminergicneuronsantipsychoticelectrophysiologicalanxiolyticInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Salutation

Applicant Name *

 

Email address *

Phone number *

 

Organization name *

Department *

 

Requested quantity *

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SB-200646
Cat. No.:
HY-103129A
Quantity:
MCE Japan Authorized Agent: